Zacks Research Issues Optimistic Estimate for PCRX Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Research analysts at Zacks Research boosted their Q4 2026 earnings per share (EPS) estimates for shares of Pacira BioSciences in a report released on Tuesday, February 11th. Zacks Research analyst R. Department now forecasts that the company will earn $0.83 per share for the quarter, up from their previous estimate of $0.79. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.40 per share.

Several other research firms also recently weighed in on PCRX. Barclays lowered their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Needham & Company LLC increased their target price on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $22.78.

Pacira BioSciences Stock Down 1.7 %

Shares of NASDAQ PCRX opened at $26.78 on Thursday. The stock has a market capitalization of $1.24 billion, a P/E ratio of -13.25 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences has a one year low of $11.16 and a one year high of $31.67. The firm’s 50 day simple moving average is $21.72 and its two-hundred day simple moving average is $18.06.

Institutional Trading of Pacira BioSciences

Hedge funds have recently modified their holdings of the business. Pacer Advisors Inc. lifted its position in Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after acquiring an additional 2,799,434 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Pacira BioSciences by 269.7% during the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after purchasing an additional 288,662 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Pacira BioSciences during the third quarter valued at approximately $793,000. Empowered Funds LLC bought a new stake in shares of Pacira BioSciences in the 3rd quarter worth approximately $3,286,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Pacira BioSciences in the 3rd quarter worth approximately $493,000. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.